BioMarin Hopes A Single Warranty Will Make Gene Therapy Reimbursement Simpler
Firm Is Offering Same Outcomes-Based Deal To All Payers
The management team talked to Scrip at J.P. Morgan about plans for launching the first gene therapy for hemophilia A in Europe and the US, and its unique approach to reimbursement.
